ArticleIndian pediatrics2026
Trends in Weight and Triceps Skinfold Thickness During Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the weekly trends in weight and triceps skinfold thickness (TSFT) in children with acute lymphoblastic lymphoma (ALL) during induction chemotherapy.
methodsChildren aged 1 month to 15 years with ALL were followed up during induction phase of chemotherapy. Weight and TSFT were recorded at baseline and on days 8, 15, 22, 29, and 35 and trends of the same were analyzed.
resultsA total of 101 children with median (q1, q3) age 6 (3, 11) years were assessed at baseline, and 95 were assessed on day 8 of induction. The weight loss and TSFT depletion were observed in 74 (77.8%) and 60 (63.1%), respectively, at any time during induction, peaking in severity within the first week of induction therapy. Treatment interruptions were observed in 60.8% children who had weight loss and/or TSFT depletion. Almost 54% and 42% children did not regain baseline weight and TSFT by the end of induction. Standard risk and age < 6.5 years were associated with decreased risk of weight loss and TSFT depletion.
conclusionOlder children are prone to weight loss and sarcopenic wasting during induction phase of chemotherapy for ALL.
Indexed as
Identifiers
41811421What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.